Acute agitation in schizophrenia is one of the harder problems in psychiatric medicine to treat well. The episodes are unpredictable, they put both patients and staff at risk, and the standard responses — intramuscular antipsychotics or benzodiazepines — work but carry sedation, injection, and the coercion of a needle into the equation. BioXcel Therapeutics built its Phase 3 program around a different idea: a thin film that dissolves under the tongue and delivers dexmedetomidine, an alpha-2 adrenergic agonist long used as an intravenous sedative in critical care. The registry record for that pivotal study, SERENITY I (NCT04268303), is now public with full results, and it offers an unusually clean look at how the drug performed.
The trial was a multicenter, randomized, double-blind, placebo-controlled study — the design label on the registry reads “quadruple” masking, meaning participants, care providers, investigators, and outcome assessors were all blinded. That is the gold-standard configuration for a subjective endpoint like agitation, where expectation can color a rating. The study enrolled 380 adults aged 18 to 75 with agitation associated with schizophrenia, schizoaffective disorder, or schizophreniform disorder, and randomized them across three arms: a 120-microgram sublingual film, a 180-microgram film, and a matching placebo film. Cognitive Research Corporation served as the clinical collaborator. Enrollment ran from January to May 2020, and the study completed quickly because the question it asked was deliberately narrow.
A two-hour endpoint, by design
Agitation is an acute state, so the trial measured an acute response. The primary endpoint was the change from baseline in the Positive and Negative Syndrome Scale – Excited Component (PEC) total score at two hours after a single dose. The PEC is a five-item subscale drawn from the broader PANSS instrument; it captures the symptoms that define an agitation episode — excitement, tension, hostility, uncooperativeness, and poor impulse control — and scores them so that a higher number means worse agitation. Because the whole point of an as-needed agitation treatment is speed, anchoring the primary readout at two hours rather than days is the right call: clinicians need to know whether the film works inside the window of an actual episode.
The baseline scores were tightly matched, which is what randomization is supposed to deliver. All three arms entered the study with mean PEC totals of roughly 17.5 to 17.6, indicating a genuinely agitated population rather than a borderline one. That matters because a low-symptom cohort can make any drug look effective simply by leaving little room to get worse.
What the evidence shows
At two hours, the placebo arm improved by 4.7 points on the PEC — a reminder that agitation episodes often de-escalate on their own once a patient is in a calm clinical setting. Against that backdrop, both active doses separated clearly. The 120-microgram film produced a mean reduction of 8.4 points, and the 180-microgram film produced a 10.4-point reduction. In plain terms, the higher dose cut the agitation score by more than twice what placebo achieved, and the lower dose still delivered nearly double the placebo effect. The dose-response relationship — bigger drop at the higher dose — is exactly the pattern regulators look for as evidence that the drug, not chance or the setting, is doing the work.
The registry's secondary analyses trace the time course of that effect across the hours surrounding the two-hour mark, and the active arms stay ahead of placebo throughout. The 180-microgram dose consistently shows the largest separation, with reductions building from the early post-dose timepoints out toward the later assessments. For a sublingual film, the implication is meaningful: the formulation is absorbing fast enough to produce a measurable calming effect well within the clinically relevant window.
The safety column nobody should skip
Dexmedetomidine's whole therapeutic profile is sedation, so the safety question is not whether it sedates but whether it sedates too much — alpha-2 agonists can lower blood pressure and heart rate, and that is the dose-limiting concern for any agitation product built on this mechanism. The headline safety figure from the posted results is notable for what it lacks: across all three arms — 129 patients on 120 micrograms, 126 on 180 micrograms, and 126 on placebo — the registry records zero serious adverse events. That does not mean the drug is free of side effects; sublingual dexmedetomidine is known to cause somnolence, dry mouth, and reductions in blood pressure, and those non-serious effects are the practical trade-off of using a sedative to treat agitation. But the absence of any serious events in a 380-patient acute-dosing study is a reassuring data point for a population and a setting where over-sedation is the chief worry.
Why this trial matters
SERENITY I is a textbook example of a tightly scoped pivotal study: one acute endpoint, one validated instrument, a blinded design, a dose-response signal, and a clean serious-adverse-event column. The evidence on the registry supports a specific, modest claim — that a single sublingual dose of dexmedetomidine meaningfully reduces acute agitation in schizophrenia within two hours relative to placebo — and it is careful not to overreach beyond that. For a field where the alternatives so often involve an injection, a non-invasive film that a patient can take cooperatively is a clinically attractive proposition, and the trial data give it an evidentiary spine. The full record, including the per-timepoint PEC tables and the adverse-event listings, is posted on the ClinicalTrials.gov study page, which remains the canonical source for anyone who wants to read the numbers rather than the summary.